Scalper1 News
An advisory panel to the Food and Drug Administration voted 12-1 in favor of approving Vertex Pharmaceuticals’ (VRTX) cystic-fibrosis drug Orkambi Tuesday afternoon. The FDA has until July 5 to decide on approval, but it usually follows the recommendations of its panels. So much buzz surrounded the event that trading in Vertex stock was halted all day Tuesday while the panel debated the issues. Orkambi is a combination of Vertex’s drug Kalydeco, Scalper1 News
Scalper1 News